文献速递消化道肿瘤与早癌消化内镜

内镜下切除的高危T1结直肠癌术后手术的影响:一项模拟目标试验的结果

Impact of surgery after endoscopically resected high-risk T1 colorectal cancer: results of an emulated target trial.
PubMed 文献 · Gastrointest Endosc · 2023-10-02

该研究利用14家三级中心2012年3月至2019年8月间内镜下切除高危T1结直肠癌患者的常规数据,模拟目标试验比较追加手术与单纯监测的长期结局。共纳入197例,手术组107例、监测组90例,48个月时复合终点(复发或死亡)在逆概率加权后两组无显著差异(加权HR 0.95,95%CI 0.52-1.75)。作者认为高危T1结直肠癌初始内镜切除后追加手术可能无获益。

要点

  • 高危T1结直肠癌内镜切除后追加手术与单纯监测相比,48个月复发或死亡无显著差异(加权HR 0.95,95%CI 0.52-1.75)。
  • 手术组107例中4例(3.7%)死亡、4例(3.7%)复发;监测组90例中6例(6.7%)死亡、4例(4.4%)复发。
  • 作者认为高危T1结直肠癌初始内镜切除后追加手术可能无获益。

核心结论

  • 本研究提示高危T1结直肠癌初始内镜切除后追加手术可能无获益。

研究设计与样本

  • 利用常规数据模拟目标试验,比较内镜切除高危T1结直肠癌后追加淋巴结清扫手术(治疗组)与单纯监测(对照组)。
  • 纳入14家三级中心2012年3月至2019年8月间内镜下切除高危T1结直肠癌的患者,共197例,治疗组107例、对照组90例。
  • 主要结局为48个月时癌症复发或死亡的复合终点。

主要发现

  • 从基线至48个月,治疗组107例中4例(3.7%)死亡,对照组90例中6例(6.7%)死亡。
  • 治疗组107例中4例(3.7%)发生癌症复发,对照组90例中4例(4.4%)发生癌症复发。
  • 经逆概率治疗加权平衡基线协变量后,两组死亡与癌症复发率无显著差异(加权风险比0.95;95%置信区间0.52-1.75)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We aimed to compare the long-term outcomes of patients with high-risk T1 colorectal cancer (CRC) resected endoscopically who received either additional surgery or surveillance. METHODS: We used data from routine care to emulate a target trial aimed at comparing 2 strategies after endoscopic resection of high-risk T1 CRC: surgery with lymph node dissection (treatment group) versus surveillance alone (control group). All patients from 14 tertiary centers who underwent an endoscopic resection for high-risk T1 CRC between March 2012 and August 2019 were included. The primary outcome was a composite outcome of cancer recurrence or death at 48 months. RESULTS: Of 197 patients included in the analysis, 107 were categorized in the treatment group and 90 were categorized in the control group. From baseline to 48 months, 4 of 107 patients (3.7%) died in the treatment group and 6 of 90 patients (6.7%) died in the control group. Four of 107 patients (3.7%) in the treatment group experienced a cancer recurrence and 4 of 90 patients (4.4%) in the control group experienced a cancer recurrence. After balancing the baseline covariates by inverse probability of treatment weighting, we found no significant difference in the rate of death and cancer recurrence between patients in the 2 groups (weighted hazard ratio, .95; 95% confidence interval, .52-1.75). CONCLUSIONS: Our study suggests that patients with high-risk T1 CRC initially treated with endoscopic resection may not benefit from additional surgery.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Corre F, Albouys J, Tran VT, et al. Impact of surgery after endoscopically resected high-risk T1 colorectal cancer: results of an emulated target trial. Gastrointest Endosc. 2023. PMID: 37793506. doi:10.1016/j.gie.2023.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。